However, when iNOS inhibitors were administered alongside the PARP inhibitors, the expected neuroprotective effects were negated, revealing a previously unknown detrimental relationship between iNOS and PARP in the context of cerebral ischemia. The gene discussed is NOS2; the disease is brain ischemia.